We are launching Syvazul BTV, a vaccine for the bluetongue virus

Syvazul® BTV is the first vaccine registered by Laboratorios Syva through the EU centralised registration procedure. Marketing approval was issued on 9th January 2019.
The vaccine is presented in the form of injectable suspension and is indicated for:
- Active immunization of ovine livestock to prevent viraemia and reduce the clinical signs and lesions caused by serotypes 1 and/or 8 of the bluetongue virus or to reduce viraemia and the clinical signs and lesions caused by bluetongue virus serotype 4.
- Active immunization of bovine livestock to prevent viraemia caused by serotypes 1 and/or 8 of the bluetongue virus or to reduce viraemia* caused by serotype 4 of bluetongue virus.
The most important advantage of Syvazul® BTV is its flexible use as a monovalent or combined vaccine. In this latter case, the product will contain a maximum of two of the three inactivated virus strains mentioned above, which will enable two strains to be vaccinated in just one injection.
Sheep can be vaccinated subcutaneously from 3 months of age. Cows can be vaccinated via the intramuscular route from 2 months of age. Vaccination can be performed during gestation and breastfeeding.
The recommendation for vaccination is as follows:
Sheep:
-First vaccination: administer a single 2 mL dose.
-Repeat vaccination: administer one 2 mL dose after 12 months.
Cows:
– First vaccination: administer two 4 mL doses 3 weeks apart.
– Repeat vaccination: administer one 4 mL dose after 12 months.
Syvazul® BTV is available in polypropylene vials that contain 80 and 200 mL.
See the specifications: https://syva.es/producto/syvazul-btv-suspension-inyectable/
You may also be interested in

2 March, 2023
SYVA announces its partnership with the biotech SMIVET for the development of SDA [SDA]
León - Technology Park – Spain, March 2, 2023 - SYVA and SMIVET signed a collaboration agreement that allow both companies to develop therapeutic solutions based on Single Domain Antibodies (SDA). With this agreement, Syva expresses its willingness to invest in new biotechnologies with the objective to continue to grow and improve its attractiveness by researching, developing, and producing...

15 February, 2023
The earthquake in Turkey affected Syva’s collaborators
From Syva we are wholeheartedly with our colleagues and The Turkish population. We want to express our support in this difficult time. We continue daily to analyse the situation and we evaluate with our contact in Turkey, how we can best support them.
23 December, 2022
Merry Christmas and a Happy New Year 2023!
Time flies and here we are already on the eve of Christmas and New Year’s celebrations for most people around the world. It’s time for us to take a little rest with our families and to wish you wonderful festivities with your family, friends, and why not at home watching a good movie. Each one according to its...